C. Conway

661. Vagus nerve stimulation reduces suicidal ideation in markedly treatment-resistant depression: RECOVER findings

Abstract Background Individuals with markedly treatment-resistant depression (mTRD) have substantial risk for suicide attempt and completion. Few antidepressant treatments offer benefit for suicide, and it is critical that novel treatments not increase/worsen suicidal ideation (SI) or behavior. Aims & Objectives Assess...

Durability of Implanted Cervical Vagus Nerve Stimulation in Treatment-resistant Major Depression: Summary of Findings and Potential Mechanisms of Action

655. Toward a brief, sensitive tool to assess depressive symptom outcomes in research and clinical practice: lessons from the RECOVER trial

Abstract Background In RECOVER, a 12-month, double-blind, randomized, controlled trial (RCT) comparing active versus sham adjunctive vagus nerve stimulation (VNS) in persons with markedly treatment-resistant depression (mTRD), total scores on the Quick Inventory of Depressive Symptomology–Clinician (QIDS-C) and –Self-R...

The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, and Future Directions.

This review summarizes the RECOVER trial's key findings and their clinical and research implications. RECOVER was a 12-month triple-blind randomized trial in adults with markedly treatment-resistant major depressive disorder (N=493; at least four failed trials in the current episode) that compared adjunctive active and...